Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population

Novo Nordisk A/S378 enrolled

Overview

This trial is conducted in the United States of America (USA). The aim of this trial is to to determine whether insulin aspart can be used effectively and safely in paediatric patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

378

Conditions

Diabetes Diabetes Mellitus, Type 1

Interventions

insulin humanDRUG

insulin lisproDRUG

insulin aspartDRUG

Eligibility

Sex: ALLMin age: 6 YearsMax age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Pediatric patients with Type 1 diabetes for at least one year * HbA1c less than 12% * Willing to administer at least 3 injections per day * Willing to perform self monitored blood glucose (SMBG) at least 4 times per day, includes subject and/or parent/guardian, as necessary

Locations (76)

Outcomes

Primary Outcomes

HbA1c (glycosylated haemoglobin A1c)

Secondary Outcomes

FPG (fasting plasma glucose)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.